Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents

Finkelsztejn, Alessandro; Gabbai, Alberto Alain; Fragoso, Yara Dadalti; Carrá, Adriana; Macías-Islas, Miguel Angel; Arcega-Revilla, Raul; García-Bonitto, Juan; Oehninger-Gatti, Carlos Luis; Orozco-Escobar, Geraldine; Tarulla, Adriana; Vergara, Fernando; Vizcarra, Darwin.
Arq. neuropsiquiatr ; 70(10): 799-806, Oct. 2012. ilus, tab
Artículo en Inglés | LILACS | ID: lil-651596

Documentos relacionados

  1. Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.
  2. In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim.
  3. Ocrelizumab for multiple sclerosis.
  4. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
  5. Prediction of relapse activity when switching to cladribine for multiple sclerosis.
  6. Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
  7. Disability progression <i>in relapse-free</i> multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
  8. Relapse-associated worsening in a real-life multiple sclerosis cohort: the role of age and pyramidal phenotype.
  9. Changes in the Expression of TGF-Beta Regulatory Pathway Genes Induced by Vitamin D in Patients with Relapsing-Remitting Multiple Sclerosis.
  10. Double immune reconstitution therapy: Cladribine after alemtuzumab in the treatment of multiple sclerosis.